Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Pyrvinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.98 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | BDKRB2 known ✓ | P30411 | 1/20 | 0.98 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.98 |
| ▸ | ACHE known ✓ | P22303 | 9/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.98 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | SYNJ1 | O43426 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | MAOA | P21397 | 1/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | NPY1R | P25929 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrvinium SCHEMBL646419 | 1.00 | AR (0.98) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL16291465 | 0.99 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL149062 | 0.99 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL149063 | 0.99 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL30642307 | 0.99 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL30383133 | 0.99 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL29387513 | 0.99 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL21111996 | 0.98 | AR (0.98) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL4877919 | 0.93 | AR (0.89) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL19457668 | 0.93 | AR (0.89) | ARSYNJ2MLNRSYNJ1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12447147-B2 | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | THOMAS JEFFERSON UNIVERSITY (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025202940-A2 | ANTIPARASITIC CYCLIC DEPSIPEPTIDES | ANIMOL DISCOVERY, INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| EP-3525590-B1 | PESTICIDAL AND PARASITICIDAL VINYL ISOXAZOLINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-20250243197-A1 | Anthelmintic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-31 | — | — | US | disclosed |
| WO-2025149943-A1 | ANTIPARASITIC CYCLIC DEPSIPEPTIDES | ANIMOL DISCOVERY, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025120611-A1 | ANTIPARASITIC COMPOUNDS | ANIMOL DISCOVERY, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12312356-B2 | Anthelmintic heterocyclic compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12269822-B2 | Anthelminthic heterocyclic compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-04-08 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM1 4575/4885CHRM3 4299/4885SLC6A2 2841/4885 |
| US-12447147-B2 | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | RNASE1, PDXK, PNLIP | CHRM1 2280/4885CHRM3 909/4885SLC6A2 4154/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CHRM1 4394/4885CHRM3 3926/4885SLC6A2 3073/4885 |
| US-12312356-B2 | Anthelmintic heterocyclic compounds | AADAC, HNMT, HRH4 | CHRM1 2868/4885CHRM3 2030/4885SLC6A2 3042/4885 |
| US-12269822-B2 | Anthelminthic heterocyclic compounds | SDHA, PAH, PIGS | CHRM1 2014/4885CHRM3 2251/4885SLC6A2 3313/4885 |
| US-20250243197-A1 | Anthelmintic Heterocyclic Compounds | PAH, PIGS, SDHA | CHRM1 1724/4885CHRM3 2072/4885SLC6A2 3645/4885 |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | HDAC5, NR5A2, HRH4 | CHRM1 483/4885CHRM3 785/4885SLC6A2 2219/4885 |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | CHRM1 2615/4885CHRM3 1395/4885SLC6A2 4625/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM1 4583/4885CHRM3 4193/4885SLC6A2 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.